Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 7/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PRKDC | P78527 | 1/20 | 0.38 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.35 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30054303 | 1.00 | ERN1 (0.41) | ERN1LMNAPRKDCTRIM24TRIM33 | |
| SCHEMBL15332623 | 0.83 | ERN1 (0.41) | ERN1LMNAPRKDCTRIM24TRIM33 | |
| SCHEMBL31252016 | 0.79 | ALDH1A1 (0.31) | — | |
| SCHEMBL1533918 | 0.78 | TDP1 (0.40) | ERN1TDP1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL29411231 | 0.78 | LMNA (0.41) | ERN1LMNAPRKDCTRIM24TRIM33 | |
| SCHEMBL30589401 | 0.78 | TDP1 (0.40) | ERN1TDP1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL19794988 | 0.78 | LMNA (0.41) | ERN1LMNAPRKDCTRIM24TRIM33 | |
| SCHEMBL24458114 | 0.75 | ERN1 (0.35) | ERN1TDP1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6856975 | 0.75 | ERN1 (0.34) | ERN1TDP1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1389512 | 0.75 | ERN1 (0.48) | ERN1LMNATRIM24TRIM33TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025237891-A1 | QUINOLINE-2-CARBOXAMIDE DERIVATIVES AS RAD51 INHIBITORS FOR THE TREATMENT OF CANCER | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2025-11-20 | — | — | WO | disclosed |
| US-20250163043-A1 | CDK9 INHIBITOR AND USE THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2025-05-22 | — | — | US | disclosed |
| EP-4217356-B1 | CYCLIN-DEPENDENT KINASE 7 (CDK7) NON-COVALENT INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2025-05-14 | — | — | EP | disclosed |
| US-20240376058-A1 | GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2024-11-14 | — | — | US | disclosed |
| EP-4450501-A1 | CDK9 INHIBITOR AND USE THEREOF | TransThera Sciences (Nanjing), Inc. (CN) | 2024-10-23 | — | — | EP | disclosed |
| US-20240262822-A1 | WDR5 INHIBITORS AND MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-08-08 | — | — | US | disclosed |
| WO-2024118460-A1 | ADENOSINE A2A AND A2B RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-06-06 | — | — | WO | disclosed |
| US-20240158415-A1 | AMINOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | HIBERCELL INC (US) | 2024-05-16 | — | — | US | disclosed |
| WO-2024097953-A1 | NAPHTHYRIDINE COMPOUNDS FOR INHIBITION OF RAF KINASES | ENLIVEN INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| US-20240101554-A1 | CYCLIN-DEPENDENT KINASE 7 (CDK7) NON-COVALENT INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-03-28 | — | — | US | disclosed |
| US-20140088076-A1 | SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-20140088076-A1 | SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-8623889-B2 | Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof | GENENTECH, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-8623889-B2 | Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof | GENENTECH, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-8623889-B2 | Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof | GENENTECH, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| EP-2651899-A2 | SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF | F.HOFFMANN-LA ROCHE AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| US-20120322785-A1 | SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120322785-A1 | SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120322785-A1 | SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2012-12-20 | — | — | US | disclosed |
| WO-2012080284-A2 | SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240262822-A1 | WDR5 INHIBITORS AND MODULATORS | WDR5, WDR1, WDR3 | ERN1 1405/4885LMNA 3249/4885PRKDC 2946/4885 |
| US-20240158415-A1 | AMINOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | PIP5K1B, PIP5K1A, PIP5K1C | ERN1 831/4885LMNA 4267/4885PRKDC 832/4885 |
| US-20120322785-A1 | SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF | XDH, CYP2B6, COX6B1 | ERN1 2368/4885LMNA 1213/4885PRKDC 4759/4885 |
| US-20240376058-A1 | GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF | EIF2AK4, GCN1, EEF2K | ERN1 9/4885LMNA 992/4885PRKDC 183/4885 |
| US-20240101554-A1 | CYCLIN-DEPENDENT KINASE 7 (CDK7) NON-COVALENT INHIBITORS | CDK7, CDK9, CDK1 | ERN1 879/4885LMNA 1570/4885PRKDC 402/4885 |
| US-20140088076-A1 | SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF | XDH, CYP2B6, COX6B1 | ERN1 2368/4885LMNA 1213/4885PRKDC 4759/4885 |
| US-20250163043-A1 | CDK9 INHIBITOR AND USE THEREOF | CDK9, CDK19, CDKL1 | ERN1 1194/4885LMNA 224/4885PRKDC 865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.